Checkpoint Therapeutics
CKPT
CKPT was delisted on the 29th of May, 2025.
69 hedge funds and large institutions have $32.3M invested in Checkpoint Therapeutics in 2021 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 20 closing their positions.
27% more call options, than puts
Call options by funds: $819K | Put options by funds: $647K
0.85% less ownership
Funds ownership: 2.38% → 1.52% (-0.85%)
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
1% less funds holding
Funds holding: 70 → 69 (-1)
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
36% less capital invested
Capital invested by funds: $50.6M → $32.3M (-$18.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.49M |
| 2 |
JSMC
Jess S. Morgan & Co
Los Angeles,
California
|
+$1.47M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$710K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$630K |
| 5 |
E
Ergoteles
New York
|
+$437K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$9.19M |
| 2 |
BlackRock
New York
|
-$7.54M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.83M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$1.13M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.05M |
CKPT Hedge Fund Activity: Q2 2021 in Review
69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q2 2021, worth a combined $32.3M — down 36% from $50.6M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CKPT and 19 opened new positions — a net loss of 1 holder — while 19 trimmed existing stakes and 17 added.
The largest buyer was Millennium Management, adding an estimated $2.49M. The largest seller was Opaleye Management, exiting entirely with an estimated $9.19M sold.
- 69 institutional investors held Checkpoint Therapeutics (CKPT) as of Q2 2021, down from 70 in Q1 2021.
- Funds reported $32.3M of Checkpoint Therapeutics stock for Q2 2021, down 36% quarter-over-quarter.
- 19 funds opened new Checkpoint Therapeutics positions in Q2 2021 and 20 closed out, a net change of -1 holder.
- The largest Checkpoint Therapeutics buyer in Q2 2021 was Millennium Management, an estimated $2.49M added.
- The largest Checkpoint Therapeutics seller in Q2 2021 was Opaleye Management, an estimated $9.19M sold.
Based on aggregated 13F filings for Q2 2021.